

# Scientific Poster Presentations III

Wednesday, October 22

8:00 a.m. – 10:00 a.m.

Convention Center: Hall 2D



## ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore presentations undergo the same peer review process as all other presentations, but they may have been presented elsewhere or published in abstract form prior to the 2008 Annual Meeting. For Encore Presentations, the abstract title, authors, and original citation (if provided) are published in *Pharmacotherapy*.

## ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

### Ambulatory Care

#### 12. A retrospective look at the effects of a pharmacist-run tobacco cessation clinic.

*Timothy C. Chen, Pharm.D., Erin Mikusky, Pharm.D., Khanh L. Nguyen, Pharm.D., Stacey Nguyen, Pharm.D., Jessica Harris, Pharm.D., Mark Bounthavong, Pharm.D.; Veterans Affairs, San Diego, CA*

### Bone Health/Osteoporosis

#### 15E. Bone mineral density and biochemical marker response rates in postmenopausal women after treatment with zoledronic acid.

*Pierre D. Delmas, M.D., Ph.D.,<sup>1</sup> I. Reid, M.D., MB, ChB,<sup>2</sup> René Rizzoli, M.D.,<sup>3</sup> Silvano Adami, M.D.,<sup>4</sup> Philip Sambrook, Ph.D.,<sup>5</sup> Erik F. Eriksen, M.D., DMSc,<sup>6</sup> Peter Mesenbrink, Ph.D.,<sup>7</sup> Richard Eastell, M.D.<sup>8</sup>; (1) Hôpital Edouard Herriot, Lyon, 69437 Lyon Cedex 03, Lyon, France; (2) University of Auckland, Auckland, New Zealand; (3) Geneva University Hospitals, Geneva, Switzerland; (4) University of Verona, Verona, Italy; (5) University of Sydney, Sydney, Australia; (6) Novartis Pharma AG, Basel, Switzerland; (7) Novartis Pharmaceuticals Corporation, East Hanover, NJ; (8) University of Sheffield, Sheffield, UK*

### Cardiovascular

#### 16. Incremental direct treatment cost of atrial fibrillation in the Medicare population.

*Won Chan Lee, Ph.D.,<sup>1</sup> Gervasio A. Lamas, M.D.,<sup>2</sup> Sanjeev Balu, Ph.D., MBA,<sup>3</sup> James Spalding, Pharm.D., M.S.,<sup>4</sup> Qin Wang, M.S.,<sup>5</sup> Chris Pashos, Ph.D.<sup>6</sup>; (1) Abt Bio-Pharma Solutions Inc., Bethesda, MD; (2) Mount Sinai Medical Center, Miami Beach, FL; (3) Abt Bio-Pharma Solutions, Lexington, MA; (4) Astellas Pharma US, Inc., Deerfield, IL; (5) Abt Bio-Pharma Solutions, Inc., Bethesda, MD; (6) Abt Bio-Pharma Solutions, Inc., Lexington, MA*

#### 17. Evaluation of a multidisciplinary comprehensive atherosclerosis management clinic.

*Cynthia A. Jackevicius, B.Sc.Pharm., M.Sc., Pharm.D., BCPS, FCSHP,<sup>1</sup> Hang Tran, Pharm.D.,<sup>1</sup> Freney Vaghaiwalla Mody, M.D.<sup>2</sup>; (1) Western University of Health Sciences, Pomona, CA; (2) Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS), Los Angeles, CA*

#### 20. Efficacy and safety of aliskiren for the treatment of hypertension.

*Benjamin W. Van Tassel, Pharm.D., BCPS,<sup>1</sup> Mark A. Munger, Pharm.D.,<sup>1</sup> Anthony Yadao, M.D.<sup>2</sup>; (1) University of Utah, College of Pharmacy, Salt Lake City, UT; (2) Novartis Pharmaceuticals Corporation, East Hanover, NJ*

#### 21. Atmospheric pressure and INR variability – are they related?

*Michael E. Ernst, Pharm.D.,<sup>1</sup> Robert F. Shaw, Pharm.D., MPH,<sup>2</sup> Erika J. Ernst, Pharm.D.,<sup>3</sup> Bruce Alexander, Pharm.D.,<sup>4</sup> Peter J. Kaboli, M.D.<sup>5</sup>; (1) College of Pharmacy and Department of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA; (2) College of Pharmacy, The University of Iowa, and Department of Pharmacy, Iowa City VA Medical Center, Iowa City, IA; (3) College of Pharmacy, The University of Iowa, Iowa City, IA; (4) Department of Pharmacy and Department of Psychiatry, Iowa City VA Medical Center, Iowa City, IA; (5) Department of Internal Medicine, Carver College of Medicine, and CRIISP at the Iowa City VA Medical Center, Iowa City, IA*

#### 22. Prevalence and pattern of caffeine use in heart failure.

*Seung H. Lee, Pharm.D.,<sup>1</sup> Jennifer I. Park, B.A.,<sup>1</sup> Karine N. Danskey, B.S.,<sup>1</sup> Luanna Yang, B.S.,<sup>1</sup> Doris S. Rezvanpour, B.S.,<sup>1</sup> Katelyn Tran, R.D., CNSD,<sup>1</sup> Sheryl L. Chow, Pharm.D.,<sup>2</sup> Uri Elkayam, M.D.,<sup>1</sup> Tien M.H. Ng, Pharm.D.<sup>1</sup>; (1) University of Southern California, Los Angeles, CA; (2) Western University of Health Sciences, Pomona, CA*

#### 23E. The combination of amlodipine/valsartan (5/160 mg) significantly reduces the incidence of peripheral edema versus amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.

*Joachim Schrader, M.D.,<sup>1</sup> Marianne Weisskopf, M.D.,<sup>2</sup> Lucy Keeling, M.S.,<sup>2</sup> Philippe Ferber, M.D.<sup>2</sup>; (1) St. Josef-Hospital, Department of Internal Medicine, Cloppenburg, Germany; (2) Novartis Pharma AG, Clinical Development & Medical Affairs, Basel, Switzerland*

#### 24E. Is the combination of valsartan/hydrochlorothiazide regimen more effective, compared to conventional treatment with amlodipine and hydrochlorothiazide, in lowering ambulatory blood pressure (BP) in patients with stage 2 hypertension? – the EVALUATE study.

*Yves Lacourciere, M.D., FRCPC, FACP,<sup>1</sup> Jackson T. Wright, Jr., M.D., Ph.D.,<sup>2</sup> Rita Samuel, M.D.,<sup>3</sup> Dion H. Zappe, Ph.D.,<sup>3</sup> Das Purkayastha, Ph.D.,<sup>3</sup> Henry R. Black, M.D.<sup>4</sup>; (1) Centre Hospitalier de l'Université Laval, Sainte Foy, QC, Canada; (2) Case Western Reserve University, Cleveland, OH; (3) Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4) New York University, School of Medicine, New York, NY*

**25E. Metabolic effects of combination angiotensin receptor blockade/hydrochlorothiazide in pre-diabetic, obese, hypertensive patients.**

Leopoldo Rajj, M.D.,<sup>1</sup> James R. Sowers, M.D.,<sup>2</sup> Ishwarlal Jialal, M.D., Ph.D.,<sup>3</sup> Brent M. Egan, M.D.,<sup>4</sup> Elizabeth Ofili, M.D., MPH,<sup>5</sup> Rita Samuel, M.D.,<sup>6</sup> Dion H. Zappe, Ph.D.,<sup>6</sup> Das Purkayastha, Ph.D.,<sup>6</sup> Prakash Deedwania, M.D.<sup>7</sup>; (1) University of Miami Miller School of Medicine, Miami, FL; (2) University of Missouri–Columbia, Columbia, MO; (3) UC Davis Medical Center, Sacramento, CA; (4) Medical University of South Carolina, Charleston, NC; (5) Morehouse School of Medicine, Atlanta, GA; (6) Novartis Pharmaceuticals Corporation, East Hanover, NJ; (7) UCSF Fresno, Fresno, CA

**26E. Impact of automated external defibrillator practical experience on 2nd year doctor of pharmacy students' performance and confidence.**

Anna Legreid Dopp, Pharm.D.,<sup>1</sup> Karen J. Kopacek, R.Ph.,<sup>2</sup> Orly Vardeny, Pharm.D.,<sup>2</sup> Daisy Dai, Pharm.D.,<sup>3</sup> Amanda L. Sweet, Pharm.D.,<sup>3</sup> John Dopp, Pharm.D.,<sup>2</sup> J. Jason Sims, Pharm.D.<sup>4</sup>; (1) Extension Services in Pharmacy, University of Wisconsin School of Pharmacy, Madison, WI; (2) Pharmacy Practice Division, University of Wisconsin School of Pharmacy, Madison, WI; (3) University of Wisconsin School of Pharmacy, Madison, WI; (4) Medtronic, Minneapolis, MN

**27E. Clopidogrel attenuates coated-platelet formation in patients undergoing elective cardiac catheterization.**

Nicholas B. Norgard, Pharm.D.,<sup>1</sup> Shoaib Saya, M.D.,<sup>2</sup> Thomas Hennebry, M.D.,<sup>3</sup> Callie Hann, B.S.,<sup>2</sup> George L. Dale, Ph.D.<sup>2</sup>; (1) University at Buffalo – School of Pharmacy and Pharmaceutical Science, Buffalo, NY; (2) University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK; (3) University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK

**28. Bivalirudin alone or in combination with eptifibatide in elective percutaneous coronary intervention.**

Abir O. Kanaan, Pharm.D.,<sup>1</sup> Steve Anisman, M.D.,<sup>2</sup> Eddison Ramsaran, M.D.,<sup>2</sup> Jennifer L. Donovan, Pharm.D.<sup>1</sup>; (1) Massachusetts College of Pharmacy and Health Sciences, Worcester, MA; (2) St. Vincent Hospital, Worcester, MA

**29. Influence of albuterol on alveolar-capillary membrane conductance in patients with heart failure.**

Eric M. Snyder, Ph.D.,<sup>1</sup> Maile L. Ceridon, B.S.,<sup>2</sup> Minelle L. Hulsebus, B.S.,<sup>2</sup> Bruce D. Johnson, Ph.D.<sup>2</sup>; (1) University of Arizona, Tucson, AZ; (2) Mayo Clinic College of Medicine, Rochester, MN

**30. Preoperative statin use is not associated with a reduced risk of atrial fibrillation after cardiac surgery.**

Brian J. Barnes, Pharm.D.,<sup>1</sup> Patricia A. Howard, Pharm.D., FCCP, BCPS (AQ, CV),<sup>1</sup> Amit Kumar, M.D.,<sup>2</sup> Michael E. Gorton, M.D.,<sup>3</sup> Scott Solomon, M.D.,<sup>2</sup> Jeffrey B. Kramer, M.D.,<sup>3</sup> Gregory F. Muehlebach, M.D.,<sup>3</sup> James L. Vacek, M.D.<sup>4</sup>; (1) School of Pharmacy, The University of Kansas, Kansas City, KS; (2) The University of Kansas Hospital, Kansas City, KS; (3) Mid-America Thoracic and Cardiovascular Surgery, Inc., The University of Kansas Hospital, Kansas City, KS; (4) Mid-America Cardiology, The University of Kansas Hospital, Kansas City, KS

**31. Effects of paroxetine on the pharmacokinetics of immediate- and extended-release metoprolol.**

Robert B. Parker, Pharm.D.,<sup>1</sup> Judith Soberman, M.D.<sup>2</sup>; (1) University of Tennessee Department of Clinical Pharmacy, Memphis, TN; (2) University of Tennessee Division of Cardiovascular Diseases, Memphis, TN

**32. Evaluation of racial disparities with statin use in veterans post-myocardial infarction.**

Amy B. Hulsey, Pharm.D.,<sup>1</sup> Robert B. Parker, Pharm.D.,<sup>2</sup> Kelly C. Rogers, Pharm.D.<sup>3</sup>; (1) VA Medical Center, Memphis, TN; (2) University of Tennessee Department of Clinical Pharmacy, Memphis, TN; (3) University of Tennessee College of Pharmacy, Memphis, TN

**34. Xanthine oxidase inhibition attenuates hypoxia-induced changes in chemoreceptor sensitization pathways.**

John M. Dopp, Pharm.D.,<sup>1</sup> Noah J. Marcus, M.S.,<sup>1</sup> Cynthia B. Bird, B.S.,<sup>1</sup> Nathan Phillipi, B.S.,<sup>1</sup> John J.M. Moran, B.S.,<sup>1</sup> E. Burt Olson, Ph.D.,<sup>1</sup> Harold D. Schultz, Ph.D.,<sup>2</sup> Yulong Li, M.D., Ph.D.,<sup>2</sup> Barbara J. Morgan, Ph.D., PT<sup>1</sup>; (1) University of Wisconsin, Madison, WI; (2) University of Nebraska College of Medicine, Omaha, NE

**35. Reductions in N-terminal prohormone brain natriuretic peptide associated with reduced risk of hospitalizations among chronic heart failure patients in an ambulatory care setting.**

Daniel E. Zamarripa, Pharm.D.,<sup>1</sup> Jessina C. McGregor, Ph.D.,<sup>2</sup> Jessie Chan, B.S.,<sup>2</sup> Harleen Singh, Pharm.D.<sup>2</sup>; (1) Portland VA Medical Center, Portland, OR; (2) Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR

**36. A pilot study to evaluate the safety and efficacy of a prothrombin complex concentrate to reverse international normalized ratios > 2 in patients requiring implantable cardiac devices.**

Denise Pratt, Pharm.D.,<sup>1</sup> Nathan Gerrish, Pharm.D. Candidate,<sup>1</sup> R.K. Thakur, M.D.,<sup>2</sup> Elizabeth Lojewski, B.S. Candidate<sup>2</sup>; (1) Sparrow Hospital, Lansing, MI; (2) Michigan State University, East Lansing, MI

**38. Evaluation of triple antithrombotic therapy after percutaneous coronary intervention (PCI) in veterans.**

Lan K. Ngo, Pharm.D.,<sup>1</sup> Shannon W. Finks, Pharm.D., BCPS,<sup>2</sup> Robert B. Parker, Pharm.D.,<sup>3</sup> Kelly C. Rogers, Pharm.D.<sup>2</sup>; (1) Veterans Affairs Medical Center, Memphis, TN; (2) University of Tennessee College of Pharmacy, Memphis, TN; (3) University of Tennessee Department of Clinical Pharmacy, Memphis, TN

**39E. Sodium derangement and associated clinical and financial outcomes: analysis of 115,969 acute heart failure admissions in 2004–2005.**

Andrew F. Shorr, M.D., MPH, FCCP,<sup>1</sup> Ying P. Tabak, Ph.D.,<sup>2</sup> Stephen G. Kurtz, M.S.,<sup>2</sup> James Spalding, Pharm.D., M.S.,<sup>3</sup> Vikas Gupta, Pharm.D., BCPS<sup>2</sup>; (1) Washington Hospital Center, Washington, DC; (2) Cardinal Health Information Services, Marlborough, MA; (3) Astellas Pharma US, Inc., Deerfield, IL

**40. Evaluation of skeletal troponin-I as an early serum marker for statin-induced myopathies.**

*Armine Khachatryan, Pharm.D., Donna Agan, Ed.D., Harminder Sikand, Pharm.D., Paul Phillips, M.D.; Scripps Mercy Hospital, San Diego, CA*

**Clinical Administration****41. Academic and training requirements in advertisements for pharmacy management and clinical director positions: a follow up.**

*John E. Murphy, Pharm.D., Jade Ashby, Pharm.D.; University of Arizona College of Pharmacy, Tucson, AZ*

**Community Pharmacy Practice****42. Attitudes of physicians toward pharmacist-provision of medication therapy management services (MTMs) as part of the Medicare Part D benefit.**

*Fadi M. Alkhateeb, Ph.D., David A. Latif, Ph.D., Renee McCafferty, Pharm.D.; University of Charleston, Charleston, WV*

**43. Patterns of pharmacy use among HIV-positive women in San Francisco.**

*Tracy P. Hsu, Pharm.D., Jennifer M. Cocohoba, Pharm.D., Ruth M. Greenblatt, M.D.; University of California, San Francisco, San Francisco, CA*

**44E. Initiative to convert patients from nebulized respiratory medications to portable inhalers: analysis of pharmacist claims for a professional fee to optimize therapy in Nova Scotia, Canada.**

*Susan K. Bowles, Pharm.D., M.Sc.,<sup>1</sup> Chris Cameron, B.Sc., M.Sc.,<sup>2</sup> Charmaine C. Cooke, B.Sc.(Pharm.), M.Sc.,<sup>3</sup> Ingrid Sketris, Pharm.D., MPA (HSA),<sup>4</sup> Priti Flanagan, Pharm.D.<sup>5</sup>; (1) Dalhousie University and Centre for Health Care of the Elderly, Halifax, NS, Canada; (2) Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada; (3) Population Health Research Unit, Dalhousie University, Halifax, NS, Canada; (4) College of Pharmacy, Dalhousie University, Halifax, NS, Canada; (5) Fraser Health Authority, Vancouver, BC, Canada*

**Emergency Medicine****75E. A pharmacist can improve timely administration of medications to boarded patients in the emergency department.**

*Victor Cohen, Pharm.D., BCPS, CGP,<sup>1</sup> Samantha P. Jellinek, Pharm.D., BCPS, CGP,<sup>2</sup> Lydia B. Fancher, Pharm.D., BCPS,<sup>2</sup> Antonios Likourezos, M.A., MPH,<sup>2</sup> Fred Cassera, R.Ph., MBA<sup>2</sup>; (1) Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY; (2) Maimonides Medical Center, Brooklyn, NY*

**76. Factors affecting morphine dosage in treating severe pain in the emergency department.**

*Adam D. Biggs, Pharm.D., Asad E. Patanwala, Pharm.D., Brian L. Erstad, Pharm.D., Peter Chase, M.D.; University of Arizona, Tucson, AZ*

**Health Services Research****87. Pharmacist's impact on heart failure outcomes: focus on medication and dietary sodium adherence.**

*Grace L. Earl, Pharm.D., Ruchi Banker, Pharm.D., Reena Thomas, Pharm.D., Neal Adams, Pharm.D., Andrew Peterson, Pharm.D.; University of the Sciences in Philadelphia/Philadelphia College of Pharmacy, Philadelphia, PA*

**88E. Transfusion and hospitalization outcomes in erythropoiesis stimulating agent (ESA)-treated cancer chemotherapy patients based on achieved hemoglobin (Hb) levels.**

*Kay Larholt, Sc.D.,<sup>1</sup> Tanya Burton, M.S.,<sup>1</sup> David Hoaglin, Ph.D.,<sup>1</sup> Chris Pashos, Ph.D.,<sup>1</sup> Brahim Bookhart, MBA, MPH,<sup>2</sup> Mitra Corral, M.S., MPH,<sup>2</sup> Catherine Tak Piech, MBA,<sup>2</sup> R. Scott McKenzie, M.D.<sup>2</sup>; (1) Abt Bio-Pharma Solutions, Inc., Lexington, MA; (2) Centocor Ortho Biotech Services, LLC, Bridgewater, NJ*

**89. Drug utilization and costs for erythropoietic stimulating agents in patients with breast, lung, or gastrointestinal cancer receiving chemotherapy.**

*Gosselin Antoine, M.A.,<sup>1</sup> Marie-Hélène Lafeuille, B.A.,<sup>1</sup> Brahim Bookhart, MBA, MPH,<sup>2</sup> Patrick Lefebvre, M.A.,<sup>1</sup> R. Scott McKenzie, M.D.,<sup>2</sup> Francis Vekeman, M.A.,<sup>1</sup> Catherine Tak Piech, MBA<sup>2</sup>; (1) Groupe d'Analyse, Ltée., Montreal, QC, Canada; (2) Centocor Ortho Biotech Services, LLC, Bridgewater, NJ*

**90E. Transfusion outcomes among oncology patients initiated with erythropoiesis-stimulating agents (ESAs) at baseline (BL) hemoglobin (Hb) of <10 v 10–11g/dL: data from the Dosing and Outcomes Study of Erythropoiesis-stimulating therapies (DOSE) registry.**

*Tanya Burton, M.S.,<sup>1</sup> Kay Larholt, Sc.D.,<sup>1</sup> Chris Pashos, Ph.D.,<sup>1</sup> Cyrus Peake, M.S.,<sup>1</sup> Brahim Bookhart, MBA, MPH,<sup>2</sup> Mitra Corral, M.S., MPH,<sup>2</sup> Catherine Tak Piech, MBA,<sup>2</sup> R. Scott McKenzie, M.D.<sup>2</sup>; (1) Abt Bio-Pharma Solutions, Inc., Lexington, MA; (2) Centocor Ortho Biotech Services, LLC, Bridgewater, NJ*

**Hematology/Anticoagulation****91. Enoxaparin for deep vein thrombosis prophylaxis in obese patients.**

*Ayana K. Rowley, Pharm.D., Michelle Lilliston, Pharm.D., BCPS, Barbara Hammer, Pharm.D., BCPS; Moses Cone Health System, Greensboro, NC*

**92. Age and ethnicity influence warfarin maintenance dose; a comparison of elderly African American and white patients.**

*Candice L. Garwood, Pharm.D.,<sup>1</sup> Jennifer L. Clemente, Pharm.D.,<sup>2</sup> George N. Ibe, Pharm.D. Student,<sup>1</sup> Vijay A. Kandula, Pharm.D. Student,<sup>1</sup> Peter Whittaker, Ph.D.<sup>3</sup>; (1) Wayne State University, Detroit, MI; (2) Harper University Hospital, Detroit, MI; (3) Wayne State University School of Medicine, Cardiovascular Research Institute and Department of Emergency Medicine, Detroit, MI*

## Hypertension

**101E. Combination of amlodipine besylate + olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups.**

*Suzanne Oparil, M.D.*,<sup>1</sup> David Ramstad, M.D.,<sup>2</sup> Michael Melino, Ph.D.,<sup>3</sup> James Lee, Ph.D.,<sup>3</sup> Reinilde Heyrman, M.D.<sup>3</sup>; (1) University of Alabama at Birmingham School of Medicine, Birmingham, AL; (2) Lakeview Medical Center, Suffolk, VA; (3) Daiichi Sankyo, Inc., Parsippany, NJ

**102E. High dose combination of amlodipine besylate + olmesartan medoxomil provides greater reduction in blood pressure compared with component monotherapies in subjects with and without diabetes.**

*George Bakris, M.D.*,<sup>1</sup> Stefano Mion-Bet, M.D.,<sup>2</sup> Sulekha Karki, BAMS,<sup>3</sup> James Lee, Ph.D.,<sup>3</sup> Reinilde Heyrman, M.D.<sup>3</sup>; (1) University of Chicago School of Medicine, Chicago, IL; (2) The Community Research of South Florida, Hialeah, IL; (3) Daiichi Sankyo, Inc., Parsippany, NJ

**103E. An olmesartan medoxomil-based treatment algorithm safely and effectively reduces blood pressure compared with placebo in patients with hypertension.**

*Suzanne Oparil, M.D.*,<sup>1</sup> Steven G. Chrysant, M.D.,<sup>2</sup> Dean J. Kereiakes, M.D.,<sup>3</sup> Jianbo Xu, M.S.,<sup>4</sup> Kathleen J. Chavanu, Pharm.D.,<sup>4</sup> William F. Waverczak, M.S.,<sup>4</sup> Robert Dubiel, Pharm.D.<sup>4</sup>; (1) University of Alabama at Birmingham School of Medicine, Birmingham, AL; (2) Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK; (3) The Heart Center of Greater Cincinnati and The Lindner Center at The Christ Hospital, Cincinnati, OH; (4) Daiichi Sankyo, Inc., Parsippany, NJ

**104E. Combination of amlodipine besylate and olmesartan medoxomil significantly reduces blood pressure in patients with hypertension independent of age.**

*Steven G. Chrysant, M.D.*,<sup>1</sup> James Rhyne, M.D.,<sup>2</sup> Michael Melino, Ph.D.,<sup>3</sup> James Lee, Ph.D.,<sup>3</sup> Reinilde Heyrman, M.D.<sup>3</sup>; (1) Oklahoma Cardiovascular & Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK; (2) The Lipid Center, Statesville, NC; (3) Daiichi Sankyo, Inc., Parsippany, NJ

**105E. An olmesartan medoxomil-based treatment algorithm safely and effectively reduces blood pressure compared with placebo in patients with stage I hypertension.**

*Steven G. Chrysant, M.D.*,<sup>1</sup> Suzanne Oparil, M.D.,<sup>2</sup> Dean J. Kereiakes, M.D.,<sup>3</sup> Kathleen J. Chavanu, Pharm.D.,<sup>4</sup> Jianbo Xu, M.S.,<sup>4</sup> William F. Waverczak, M.S.,<sup>4</sup> Robert Dubiel, Pharm.D.<sup>4</sup>; (1) Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK; (2) University of Alabama at Birmingham School of Medicine, Birmingham, AL; (3) The Heart Center of Greater Cincinnati and The Lindner Center at The Christ Hospital, Cincinnati, OH; (4) Daiichi Sankyo, Inc., Parsippany, NJ

**106E. An olmesartan medoxomil-based treatment algorithm safely and effectively reduces blood pressure compared with placebo in patients with stage 2 hypertension.**

*Dean J. Kereiakes, M.D.*,<sup>1</sup> Suzanne Oparil, M.D.,<sup>2</sup> Steven G. Chrysant, M.D.,<sup>3</sup> Jianbo Xu, M.S.,<sup>4</sup> Kathleen J. Chavanu, Pharm.D.,<sup>4</sup> William F. Waverczak, M.S.,<sup>4</sup> Robert Dubiel, Pharm.D.<sup>4</sup>; (1) The Heart Center of Greater Cincinnati and The Lindner Center at The Christ Hospital, Cincinnati, OH; (2) University of Alabama at Birmingham School of Medicine, Birmingham, AL; (3) Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK; (4) Daiichi Sankyo, Inc., Parsippany, NJ

**107E. Long-term efficacy of a combination of amlodipine besylate plus olmesartan medoxomil: treating black patients to blood pressure goal.**

*Suzanne Oparil, M.D.*,<sup>1</sup> James Lee, Ph.D.,<sup>2</sup> Michael Melino, Ph.D.,<sup>2</sup> Reinilde Heyrman, M.D.<sup>2</sup>; (1) University of Alabama at Birmingham School of Medicine, Birmingham, AL; (2) Daiichi Sankyo, Inc., Parsippany, NJ

**108E. The long-term effect of a combination of amlodipine besylate plus olmesartan medoxomil therapy on achieving blood pressure goals in patients with diabetes.**

*George Bakris, M.D.*,<sup>1</sup> Sulekha Karki, BAMS,<sup>2</sup> James Lee, Ph.D.,<sup>2</sup> Reinilde Heyrman, M.D.<sup>2</sup>; (1) University of Chicago School of Medicine, Chicago, IL; (2) Daiichi Sankyo, Inc., Parsippany, NJ

**109E. Diurnally adjusted trough:peak analysis of diastolic blood pressure for a combination of amlodipine besylate and olmesartan medoxomil.**

*Shashank Rohatagi, Ph.D.*,<sup>1</sup> Reinilde Heyrman, M.D.,<sup>1</sup> Antonia Wang, Ph.D.,<sup>1</sup> Timothy Carrothers, Sc.D.<sup>2</sup>; (1) Daiichi Sankyo, Inc., Parsippany, NJ; (2) Pharsight Corporation, Mountain View, CA

## Managed Care

**139. Clinical consequences of suboptimal clopidogrel therapy after stent implantation in acute coronary syndrome patients: an integrated health plan's perspective.**

*Karina L. Berenson, MPH*,<sup>1</sup> Daniel Wiederkehr, B.S.,<sup>1</sup> Michelle R. Krukus, B.S.,<sup>1</sup> Lois E. Lamerato, Ph.D.,<sup>2</sup> Dinara Makenbaeva, M.D., MBA,<sup>3</sup> Essy Mozaffari, Pharm.D., MPH,<sup>4</sup> John C. Corbelli, M.D.<sup>5</sup>; (1) Analytica International, New York, NY; (2) Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI; (3) Bristol-Myers Squibb, Plainsboro, NJ; (4) Sanofi-Aventis, Bridgewater, NJ; (5) Buffalo Cardiology and Pulmonary Associates, PC, SUNY Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY

**140. Economic consequences of recurrent acute coronary syndrome-related hospitalizations.**

*Karina L. Berenson, MPH,<sup>1</sup> Augustina O. Ogbonnaya, MPH,<sup>1</sup> Roman Casciano, M.S.,<sup>1</sup> Dinara Makenbaeva, Pharm.D., M.D.,<sup>2</sup> Essy Mozaffari, Pharm.D., MPH,<sup>3</sup> Lois E. Lamerato, Ph.D.,<sup>4</sup> John C. Corbelli, M.D.,<sup>5</sup> (1) Analytica International, New York, NY; (2) Bristol-Myers Squibb, Plainsboro, NJ; (3) Sanofi-Aventis, Bridgewater, NJ; (4) Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI; (5) Buffalo Cardiology and Pulmonary Associates, PC, SUNY Buffalo School of Medicine and Biomedical Sciences, Williamsville, NY*

**141. Lipid profile changes associated with changing available formulary statins.**

*Daniel S. Longyhore, Pharm.D., BCPS, Casey McNulty, Pharm.D. Candidate; Wilkes University, Wilkes Barre, PA*

**Ophthalmology****162E. Effects of bromfenac sodium on acute and chronic uveitis in rabbits.**

*Takahiro Ogawa, Ph.D.,<sup>1</sup> Tetsuo Kida, M.Sc.,<sup>2</sup> John J. Han, Pharm.D.,<sup>3</sup> Clara K. Song, Pharm.D.,<sup>3</sup> Timothy R. McNamara, Pharm.D.,<sup>3</sup> (1) Senju USA Inc., Woodland Hills, CA; (2) Preclinical Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan; (3) ISTA Pharmaceuticals, Inc., Irvine, CA*

**Ophthalmology****163E. Effect of topical bromfenac sodium 0.1% ophthalmic solution on laser-induced choroidal neovascularization in mice.**

*Tetsuo Kida, M.Sc.,<sup>1</sup> Takahiro Ogawa, Ph.D.,<sup>2</sup> Hideyuki Sakaki, Ph.D.,<sup>1</sup> John J. Han, Pharm.D.,<sup>3</sup> Clara K. Song, Pharm.D.,<sup>3</sup> Tim R. McNamara, Pharm.D.,<sup>3</sup> (1) Preclinical Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan; (2) Senju USA Inc., Woodland Hills, CA; (3) ISTA Pharmaceuticals, Inc., Irvine, CA*

**Pediatrics****168. Effectiveness of recombinant human hyaluronidase-augmented subcutaneous hydration in children.**

*Coburn H. Allen, M.D., Andrea T. Cruz, M.D., Binita Patel, M.D., Erin E. Endom, M.D., Troy Bush, B.S., CCRP; Baylor College of Medicine and Texas Children's Hospital, Houston, TX*

**169. Safety of recombinant human hyaluronidase-augmented subcutaneous hydration in children.**

*Coburn H. Allen, M.D., Andrea T. Cruz, M.D., Binita Patel, M.D., Erin E. Endom, M.D., Troy Bush, B.S., CCRP; Baylor College of Medicine and Texas Children's Hospital, Houston, TX*

**170. Influence of home asthma maintenance therapy on frequency of pediatric hospital admissions.**

*Shirley M. Hogan, Pharm.D.,<sup>1</sup> Kim G. Adcock, Pharm.D.,<sup>1</sup> Sunil Mathur, Ph.D.,<sup>2</sup> (1) University of Mississippi, Jackson, MS; (2) University of Mississippi, University, MS*

**171E. Cognitive and sedative effects of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder.**

*John Renna, Pharm.D., M.S., R.Ph.,<sup>1</sup> Scott H. Kollins, Ph.D.,<sup>2</sup> Timothy Wigal, Ph.D.,<sup>3</sup> Bradley Vince, D.O.,<sup>4</sup> Andrew Lyne, M.Sc., CStat,<sup>5</sup> Kimberly Farrand, MPH,<sup>1</sup> Thomas Roth, Ph.D.,<sup>6</sup> (1) Shire Development Inc., Wayne, PA; (2) Duke University Medical School, Durham, NC; (3) University of California, Irvine, CA; (4) Vince and Associates Clinical Research, Overland Park, KS; (5) Shire Pharmaceutical Development LTD., Basingstoke, UK; (6) Henry Ford Hospital Sleep Disorders Center, Northville, MI*

**173E. Long-term safety and efficacy of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder.**

*Floyd R. Sallee, M.D., Ph.D.,<sup>1</sup> James J. McGough, M.D.,<sup>2</sup> Timothy Wigal, Ph.D.,<sup>3</sup> Daniel Sea, B.A.,<sup>4</sup> Andrew Lyne, M.Sc., CStat,<sup>5</sup> Joseph Biederman, M.D.,<sup>6</sup> (1) University of Cincinnati, Cincinnati, OH; (2) Neuropsychiatric Institute and David Geffen School of Medicine of UCLA, Los Angeles, CA; (3) University of California, Irvine, CA; (4) Shire Development, Inc., Wayne, PA; (5) Shire Pharmaceutical Development LTD., Basingstoke, UK; (6) Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA*

**174E. Guanfacine extended release: duration of effect in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder.**

*Floyd R. Sallee, M.D., Ph.D.,<sup>1</sup> Andrew Lyne, M.Sc., CStat,<sup>2</sup> Joseph Biederman, M.D.,<sup>3</sup> (1) University of Cincinnati, Cincinnati, OH; (2) Shire Pharmaceutical Development LTD., Basingstoke, UK; (3) Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, MA*

**175. Caffeine for prevention or treatment of alprostadil-induced apnea in infants with congenital heart disease.**

*Marcia L. Buck, Pharm.D., D. Scott Lim, M.D., Joshua Attridge, M.D.; University of Virginia Children's Hospital, Charlottesville, VA*

**176E. Evaluation of zolpidem exposures in the pediatric population.**

*Jill Griffith, Pharm.D.,<sup>1</sup> Hanna Phan, Pharm.D.,<sup>2</sup> Marcel J. Casavant, M.D.,<sup>3</sup> Milap C. Nahata, Pharm.D., FCCP,<sup>4</sup> S. David Baker, Pharm.D.,<sup>1</sup> (1) The Ohio State University College of Pharmacy; Nationwide Children's Hospital, Central Ohio Poison Control Center, Columbus, OH; (2) The Ohio State University, College of Pharmacy; The Research Institute at Nationwide Children's Hospital, Columbus, OH; (3) The Ohio State University, Colleges of Medicine and Pharmacy; The Research Institute at Nationwide Children's Hospital, Columbus, OH; (4) The Ohio State University, Colleges of Pharmacy and Medicine; The Research Institute at Nationwide Children's Hospital, Columbus, OH*

**177. Off-label medication use and associated adverse drug events in a pediatric emergency department.**

*Hanna Phan, Pharm.D.*,<sup>1</sup> Marc S. Leder, M.D.,<sup>2</sup> Matthew Fishley, B.S.,<sup>3</sup> Matthew Moeller, B.S.,<sup>4</sup> Milap C. Nahata, Pharm.D., FCCP<sup>5</sup>; (1) The Ohio State University, College of Pharmacy; The Research Institute at Nationwide Children's Hospital, Columbus, OH; (2) The Ohio State University, Department of Pediatric Emergency Medicine, College of Medicine; Nationwide Children's Hospital, Columbus, OH; (3) The Ohio State University, College of Pharmacy, Columbus, OH; (4) University of Cincinnati, The James L. Winkle College of Pharmacy, Cincinnati, OH; (5) The Ohio State University, College of Pharmacy and Medicine; The Research Institute at Nationwide Children's Hospital, Columbus, OH

**178. Effectiveness of lactobacillus GG for prevention of antibiotic-associated diarrhea in the pediatric intensive care unit.**

*Allison M. Chung, Pharm.D., BCPS, AE-C*,<sup>1</sup> Stephen Davis, Pharm.D.<sup>2</sup>; (1) Auburn University, Department of Pharmacy Practice; University of South Alabama, Department of Pediatrics, Mobile, AL; (2) The University of Pittsburgh Medical Center, Pittsburgh, PA

**179. Prematures with respiratory distress syndrome do not have increased chance of patent ductus arteriosus requiring indomethacin therapy thereafter.**

*Zon-Min Lee, Sr., Master*; Chang Gung Memorial Hospital, Taiwan, Taiwan

**Substance Abuse/Toxicology****207. Characterization of alcohol-related knowledge, behavior, and attitudes of first-year doctor of pharmacy students.**

Laurel L. Andrews, Pharm.D., Scott A. Baggarly, Ph.D., Darren A. LeBlanc, Pharm.D. Candidate, Edwin H. Adams, Pharm.D., Connie L. Smith, Pharm.D., Ann M. Wicker, Pharm.D., *W. Greg Leader, Pharm.D.*; University of Louisiana at Monroe College of Pharmacy, Monroe, LA

**Transplant/Immunology****210E. AcMPAG levels and UGT genetic variations are associated with occurrence of side effects in thoracic transplant recipients treated with mycophenolate mofetil.**

*Lillian S.L. Ting, B.Sc., M.Sc.(Pharm.), Ph.D. Student*,<sup>1</sup> Marie-Odile Benoit-Biancamano, DMV, M.Sc., Ph.D. Candidate,<sup>2</sup> Olivier Bernard, B.Sc.(Pharm.), M.Sc.,<sup>2</sup> K. Wayne Riggs, B.Sc.(Pharm.), Ph.D.,<sup>3</sup> Chantal Guillemette, Ph.D.,<sup>2</sup> Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAH<sup>4</sup>; (1) University of British Columbia, Vancouver, BC, Canada; (2) CHUL Research Centre, Laval University, Quebec City, QC, Canada; (3) University of British Columbia, Vancouver, BC, Canada; (4) University of British Columbia, BC Women's Hospital and Health Centre, Vancouver, BC, Canada

**211. Pharmacokinetics of mycophenolate and its glucuronidated metabolites in stable islet-cell transplant recipients.**

Mai Al-Khatib, B.Sc.(Pharm.), M.Sc. Student,<sup>1</sup> R. Jean Shapiro, M.D., FRCPC,<sup>2</sup> Nilufar Partovi, B.Sc.(Pharm.), Pharm.D.,<sup>3</sup> *Lillian S.L. Ting, B.Sc., M.Sc.(Pharm.), Ph.D. Student*,<sup>1</sup> Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAH<sup>4</sup>; (1) University of British Columbia, Vancouver, BC, Canada; (2) University of British Columbia, Vancouver

General Hospital, Vancouver, BC, Canada; (3) University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (4) University of British Columbia, BC Women's Hospital and Health Centre, Vancouver, BC, Canada

**212. Disparate effects of immunosuppression on influenza vaccine responses by lung transplant patients.**

*Mary S. Hayney, Pharm.D., MPH*,<sup>1</sup> Holly Thomas, B.A., MSSW,<sup>2</sup> Mary L. Francois, R.N., MSN,<sup>2</sup> Kelly L. Radford, R.N.,<sup>2</sup> John J.M. Moran, B.S.,<sup>1</sup> Keith C. Meyer, M.D.<sup>3</sup>; (1) University of Wisconsin School of Pharmacy, Madison, WI; (2) University of Wisconsin Hospital and Clinics, Madison, WI; (3) University of Wisconsin School of Medicine and Public Health, Madison, WI

**214. Seroconversion rates with an accelerated hepatitis A and/or B vaccine schedule in heart transplant candidates.**

*Sharon Sam, Pharm.D.*,<sup>1</sup> Jodie M. Fink, Pharm.D., BCPS<sup>2</sup>; (1) Cleveland Clinic, River Forest, IL; (2) Cleveland Clinic, Cleveland, OH

**215E. A survey of immunosuppressive strategies in liver transplant patients with hepatitis C virus.**

*Timothy M. Clifford, Pharm.D., BCPS*,<sup>1</sup> Hoonbae Jeon, M.D.,<sup>2</sup> Thomas D. Johnston, M.D.,<sup>2</sup> Dinesh Ranjan, M.D.,<sup>2</sup> Roberto Gedaly, M.D.<sup>2</sup>; (1) University of Kentucky Healthcare, Lexington, KY; (2) University of Kentucky Department of Surgery, Section of Transplantation, Lexington, KY

**216E. Statin therapy and corticosteroid therapy in kidney transplantation: effects on cardiovascular event and death rates.**

*Ruth-Ann M. Lee, Pharm.D.*, Adele H. Rike, Pharm.D., Rita R. Alloway, Pharm.D., Jason J. Everly, Pharm.D., Amit Govil, M.D., Janet Durbin, R.N., E. Steve Woodle, M.D.; University of Cincinnati, Cincinnati, OH

**CLINICAL PHARMACY FORUM**

These abstracts describe the delivery, development, justification, or documentation of innovative clinical pharmacy services; they may be descriptive only and need not contain an evaluative component.

**Adult Medicine****225. Implementation of a prospective pharmacist review on a hospitalist unit.**

*Melissa M. Blair, Pharm.D., BCPS, FCCP, CDE*, Jennifer E. Reel, Pharm.D., Mark E. Allen, MBA; New Hanover Regional Medical Center, Wilmington, NC

**Cardiovascular****232E. Impact of a group heart failure clinic on patient outcomes in a veteran population.**

*Adrienne Matson, Pharm.D., BCPS*,<sup>1</sup> Kate Schmoll, Pharm.D.,<sup>1</sup> Douglas T. Steinke, Ph.D.<sup>2</sup>; (1) Veterans Affairs Medical Center, Lexington, KY; (2) University of Kentucky College of Pharmacy, Lexington, KY

**233. A retrospective review of bivalirudin versus glycoprotein IIb/IIIa inhibitors plus heparin for percutaneous coronary intervention.**

*John P. Lindsley, Pharm.D.*, Kerry K. Pickworth, Pharm.D., Danielle M. Blais, Pharm.D.; The Ohio State University Medical Center, Columbus, OH

**234. Comparison of a warfarin dosing nomogram with conventional physician dosing.**

*Paul Juang, Pharm.D.*,<sup>1</sup> Kelle Turner, Pharm.D.,<sup>2</sup> Dennis Bouselli, Pharm.D.<sup>2</sup>; (1) St. Louis College of Pharmacy, St. Louis, MO; (2) Missouri Baptist Medical Center, St. Louis, MO

**Chapter Poster****235. Canadian College of Clinical Pharmacy: chapter overview and strategic initiatives.**

*Christine A. Hughes, B.Sc.Pharm., Pharm.D.*,<sup>1</sup> Linda D. Dresser, Pharm.D.,<sup>2</sup> Lisa McCarthy, B.Sc.Pharm., Pharm.D.,<sup>3</sup> Thomas E.R. Brown, Pharm.D.,<sup>4</sup> Suzanne C. Taylor, Pharm.D.,<sup>5</sup> Andrea Kent, Pharm.D.<sup>6</sup>; (1) Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada; (2) North York General Hospital, Toronto, ON, Canada; (3) McMaster Family Health Team, Hamilton, ON, Canada; (4) Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; (5) Drug Use Optimization BC Ministry of Health, Pharmaceutical Services Division, New Westminster, BC, Canada; (6) Colchester East Hants Health Authority, Truro, NS, Canada

**Clinical Administration****236. National Patient Safety Goal 3E: the utility of benchmarking in the realm of optimizing pharmacy practice and patient safety.**

*Charlene A. Hope, Pharm.D., BCPS*,<sup>1</sup> Stacy Ramga, Pharm.D., M.S.,<sup>1</sup> Karen Miller, Pharm.D.,<sup>1</sup> Lisa Prather, Pharm.D., BCPS,<sup>1</sup> Bea Dys, Pharm.D.<sup>2</sup>; (1) Comprehensive Pharmacy Services, Memphis, TN; (2) Medication Management/Comprehensive Pharmacy Services, Dracut, MA

**237. Clinical quality improvement (CQI) process on the use of erythropoiesis stimulating agents (ESAs) following the updated guideline of the Centers of Medicare & Medicaid Services (CMS) started July 2007.**

*Tiffany H. Bach, Pharm.D.*, Vuong Green, Pharm.D., Siu-Fun Wong, Pharm.D., FASHP, FCSHP; Western University of Health Sciences, College of Pharmacy, Pomona, CA

**238. Evaluation of antimicrobial stewardship programs and their relationship to pharmaceutical expenditures.**

*Lisa Prather, Pharm.D., BCPS*,<sup>1</sup> Charlene A. Hope, Pharm.D., BCPS,<sup>1</sup> Stacy Ramga, Pharm.D., M.S.,<sup>1</sup> Karen Miller, Pharm.D.,<sup>1</sup> Bea Dys, Pharm.D.<sup>2</sup>; (1) Comprehensive Pharmacy Services, Memphis, TN; (2) Medication Management/Comprehensive Pharmacy Services, Dracut, MA

**239E. Cost-benefit analysis of a novel oncology pharmacy practice model in a private medical oncology office.**

*Siu-Fun Wong, Pharm.D.*; Western University of Health Sciences, Pomona, CA

**Community Pharmacy Practice****240. On the road to improved trucker's health – road to opportunity for pharmacists.**

*John T. Johnson, Pharm.D., CDE*, Amber Watts, Pharm.D., Josh Guffey, Pharm.D.; University of Georgia College of Pharmacy, Athens, GA

**241. Positive impact of pharmacist intervention with medicare patients with diabetes – Georgia Pharmacist Association and Center for Medicare and Medicaid Services Project Outcomes.**

*John T. Johnson, Pharm.D., CDE*; University of Georgia College of Pharmacy, Athens, GA

**Critical Care****243. Impact of a severe sepsis order set on compliance with the severe sepsis bundles and subsequent outcomes.**

*Kara W. Orwig, Pharm.D.*, Thomas C. Rushton, M.D.; St. Mary's Medical Center, Huntington, WV

**244. A review of recombinant activated factor VII (NovoSeven®) use in a large community hospital.**

*Christy D. Burrows, Pharm.D.*, Vickie L. Bridges, Pharm.D., Carla A. Zeilmann, Pharm.D., BCPS; St. John's Hospital, Springfield, MO

**Emergency Medicine****248. Justification for emergency department clinical pharmacy services in a rural, tertiary medical center.**

*Benjamin Miles, Pharm.D.*, Marybeth Boudreau, Pharm.D., Jamie L. Cronin, Pharm.D., James A. Cattin, R.Ph., M.S., Dan Moellentint, Pharm.D.; Eastern Maine Medical Center, Bangor, ME

**249. Implementation of an emergency pharmacist.**

*Darrel W. Hughes, Pharm.D.*,<sup>1</sup> Pamela R. Maxwell, Pharm.D., BCPS,<sup>1</sup> Kay Green, R.Ph., BCPS,<sup>2</sup> James S. Lewis II, Pharm.D.,<sup>1</sup> Yolanda Laurel, R.Ph., MBA<sup>2</sup>; (1) University Health System, University of Texas at Austin College of Pharmacy, University of Texas Health Science Center, San Antonio, TX; (2) University Health System, San Antonio, TX

**251. Pharmacy resident and student activities in an emergency department.**

*Michael J. Peeters, Pharm.D., BCPS*; University of Toledo Medical Center, Toledo, OH

**Health Services Research****254. Patient comfort with health literacy skills assessment.**

*Jill S. Wallace, Medical Student*,<sup>1</sup> Darcie L. Keller, Pharm.D., BCPS,<sup>2</sup> Julie M. Wright, Pharm.D., FCCP<sup>1</sup>; (1) University of Missouri–Kansas City, School of Medicine, Kansas City, MO; (2) Kansas City Veterans Affairs Medical Center, Kansas City, MO

**255. A reliable scale to measure patient comfort with communicating about their health literacy status.**

*Julie M. Wright, Pharm.D., FCCP, BCPS*,<sup>1</sup> Darcie L. Keller, Pharm.D., BCPS,<sup>2</sup> Mary M. Gerkovich, Ph.D.,<sup>3</sup> Radhika K. Ravindran, Medical Student,<sup>1</sup> Jill S. Wallace, Medical Student,<sup>1</sup> Beena Shekar, Medical Student,<sup>1</sup> Mimi Moon, Medical Student,<sup>1</sup> Maria Posada, Medical Student,<sup>1</sup> Joomee Shim, Medical Student,<sup>1</sup> Heather Cha, Medical Student<sup>1</sup>; (1) University of Missouri–Kansas City, School of Medicine, Kansas City, MO; (2) Kansas City Veterans Affairs Medical Center, Kansas City, MO; (3) University of Missouri–Kansas City, Kansas City, MO

**Hematology/Anticoagulation****256. Prospective study comparing prevalence of low B12 levels in African Americans with and without sickle cell disease.**

*Salome K. Bwayo, Pharm.D.*,<sup>1</sup> Hemamalini Karpurapu, M.D.,<sup>2</sup> Suguna Chirla, M.D.,<sup>2</sup> Fredric Lombardo, Pharm.D.,<sup>1</sup> Victor Gordeuk, M.D.<sup>2</sup>; (1) Howard University School of Pharmacy, Washington, DC; (2) Howard University College of Medicine, Washington, DC

**Humanism in Medicine****258. Send in the clowns!**

*Carolyn C. Brackett, Pharm.D., BCPS*; The Ohio State University College of Pharmacy, Columbus, OH

**Infectious Diseases****259. Implementation of an extended infusion piperacillin/tazobactam policy at a tertiary academic medical center.**

*Elizabeth Marino, Pharm.D.*, Jason C. Gallagher, Pharm.D., BCPS, Stephanie J. Costante, Pharm.D., BCPS, Kazumi Morita, Pharm.D., BCPS, Courtney Vincent, Pharm.D., BCPS, Christina M. Rose, Pharm.D., BCPS; Temple University Hospital, Philadelphia, PA

**Managed Care****260. Benchmarking: leveraging best-practice strategies to implement anticoagulant and antibiotic management tools.**

*Karen Miller, Pharm.D.*,<sup>1</sup> Bea Dys, Pharm.D.,<sup>2</sup> Charlene A. Hope, Pharm.D., BCPS<sup>1</sup>; (1) Comprehensive Pharmacy Services, Memphis, TN; (2) Medication Management/Comprehensive Pharmacy Services, Dracut, MA

**Medication Safety****261. Benefit of pharmacist-obtained medication histories in the intensive care unit.**

*Jacob B. Hatch, Pharm.D.*, Jeffrey T. Fish, Pharm.D.; University of Wisconsin Hospital and Clinics, Madison, WI

**Nephrology****262. Concurrent iron supplementation with epoetin alfa treatment.**

*Salome K. Bwayo, Pharm.D.*, Bisrat Hailemeskel, Pharm.D., Anthony K. Wutoh, Ph.D., Euni Lee, Ph.D., Pharm.D.; Howard University School of Pharmacy, Washington, DC

**263. Implementation of a template ordering process to improve medication safety with erythropoiesis stimulating agents (ESAs) in a veteran population.**

*Heather Ourth, Pharm.D., CGP*,<sup>1</sup> Matthew Cantrell, Pharm.D.<sup>2</sup>; (1) VA Central Iowa Healthcare, Des Moines; (2) VA Medical Center, Iowa City, IA

**Pediatrics****264. Evaluation of the current treatment of neonatal abstinence syndrome (NAS) and development of a standard of care for the neonatal intensive care unit (NICU).**

*Brian Curran, Pharm.D.*,<sup>1</sup> Paul Mangino, Pharm.D.,<sup>2</sup> Lori A. Devlin, D.O.<sup>2</sup>; (1) Mayo Clinic, Rochester, MN; (2) University of Louisville Healthcare, Louisville, KY

**265. A clinical pharmacist's role in screening for metabolic syndrome in a pediatric ambulatory clinic.**

*Sandra Benavides, Pharm.D.*,<sup>1</sup> Garry Souffrant, M.D.<sup>2</sup>; (1) Nova Southeastern University, Ft. Lauderdale, FL; (2) Su Clinica Familiar, Harlingen, TX

**Pharmacoeconomics/Outcomes****267E. Cost-effectiveness of colesevelam HCl plus metformin compared with metformin alone using a validated model from a third-party payer perspective in the USA.**

*Michael E. Minshall, MPH*,<sup>1</sup> Michael Hagan, Ph.D.,<sup>2</sup> Kevin Mayo, Ph.D.,<sup>2</sup> Sam Misir, Pharm.D.,<sup>2</sup> Meaghan St. Charles, Ph.D.<sup>1</sup>; (1) IMS Health®, Noblesville, IN; (2) Daiichi Sankyo, Inc., Parsippany, NJ

**268. Cost savings through implementation of low-flow inhalation in general anesthesia.**

*Stephanie N. Davis, Pharm.D.*,<sup>1</sup> Heidi Smith, Pharm.D.,<sup>2</sup> Lois Connolly, M.D.,<sup>3</sup> Harvey Woehlck, M.D.<sup>3</sup>; (1) Pharmacy Healthcare Solutions, Madison, WI; (2) Froedter Memorial Lutheran Hospital, Milwaukee, WI; (3) Medical College of Wisconsin, Milwaukee, WI

**Regional Chapter Issues****269E. Expanding the frontiers of ACCP regional chapter membership: Northern California College of Clinical Pharmacy's experience in 2007.**

*Tina Denetclaw, Pharm.D., BCPS*,<sup>1</sup> Katherine Yep, Pharm.D.,<sup>2</sup> Sharya Bourdet, Pharm.D., BCPS,<sup>3</sup> Jodi Bryner, Pharm.D.,<sup>4</sup> Scott Pollock, Pharm.D., B.S.,<sup>5</sup> Audrey Lee, Pharm.D., BCPS,<sup>3</sup> Cecily Allmon, Pharm.D.,<sup>2</sup> Wendy Sui, Pharm.D. Student,<sup>6</sup> Christine Bang, Pharm.D. Student,<sup>6</sup> Ellena Mar, Pharm.D. Student,<sup>7</sup> Helen Kim, Pharm.D. Student,<sup>7</sup> Stephanie Yoo, Pharm.D. Student,<sup>7</sup> Michelle Ho, Pharm.D. Student,<sup>8</sup> Allen Ho, Pharm.D. Student,<sup>8</sup> Joy Pimentel, Pharm.D. Student,<sup>8</sup> Yvonne Phan, Pharm.D. Student<sup>8</sup>; (1) Marin General Hospital, El Sobrante, CA; (2) California Pacific Medical Center, San Francisco,

CA; (3) Veterans Medical Center, San Francisco, CA; (4) Kaiser Permanente, Walnut Creek, CA; (5) Johnson & Johnson, San Francisco, CA; (6) University of California, San Francisco, CA; (7) Touro University College of Pharmacy, Mare Island, CA; (8) University of the Pacific School of Pharmacy, Stockton, CA

### Regional Chapter Report

#### 270. Mid-South College of Clinical Pharmacy: enhancing clinical pharmacy practice for our members.

*Joseph M. Swanson, Pharm.D., BCPS,<sup>1</sup> Shannon W. Finks, Pharm.D., BCPS,<sup>1</sup> Amy H. Manguso, Pharm.D.,<sup>2</sup> Carrie S. Oliphant, Pharm.D., BCPS<sup>3</sup>; (1) University of Tennessee Health Science Center, Memphis, TN; (2) Baptist Memorial Healthcare–Memphis, Memphis, TN; (3) Methodist University Hospital, Memphis, TN*

### RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

These papers describe original research by residents and fellows in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoepidemiology, and pharmacogenomics in which the research effort is still on-going.

### Cardiovascular

#### 273. Use of heparin levels versus aPTT in patients with acute coronary syndrome.

*Leslie A. Hamilton, Pharm.D., Julie B. Cooper, Pharm.D., BCPS; Moses H. Cone Health System, Greensboro, NC*

#### 274. Effect of hydrochlorothiazide on endothelial expression of insulin signaling genes.

*Julio D. Duarte, Pharm.D.,<sup>1</sup> Issam Zineh, Pharm.D.<sup>2</sup>; (1) University of Florida College of Pharmacy, Gainesville, FL; (2) University of Florida College of Pharmacy Department of Pharmacy Practice and Center for Pharmacogenomics, Gainesville, FL*

## Best Poster Finalists

All Best Poster Finalists will have their posters displayed Monday, October 20, Tuesday, October 21, and Wednesday, October 22. Finalists will present their posters on Tuesday, October 21 from 8:00 a.m. – 10:00 a.m. The presentation of the Best Poster Award will be on Tuesday, October 21 at 9:45 a.m.

#### 53F. Lipid administration in the VELOCITY trial: safety and efficacy of cleveldipine butyrate intravenous emulsion in acute, severe hypertension.

*Joseph F. Dasta, M.Sc., R.Ph.,<sup>1</sup> Jay M. Mirtallo, M.S., R.Ph.<sup>2</sup>; (1) University of Texas, Hutto, TX; (2) The Ohio State University Medical Center, Columbus, OH*

#### 120F. CAS5 is required for fluconazole tolerance in *Candida albicans*.

*Nathan P. Wiederhold, Pharm.D.,<sup>1</sup> Katherine S. Barker, Ph.D.,<sup>2</sup> Jonathan Bain, B.S.,<sup>2</sup> Vincent M. Bruno, Ph.D.,<sup>3</sup> Aaron P. Mitchell, Ph.D.,<sup>3</sup> P. David Rogers, Pharm.D., Ph.D.<sup>2</sup>; (1) The University of Texas at Austin College of Pharmacy and The University of Texas Health Science Center at San Antonio, San Antonio, TX; (2) University of Tennessee, Memphis, TN; (3) Columbia University, New York, NY*

#### 153F. Role of renal function and pharmacogenomics on mycophenolic acid pharmacokinetics in patients with glomerular diseases.

*Melanie S. Joy, Pharm.D.,<sup>1</sup> Jinzhao Wang, B.S.,<sup>2</sup> Tandra Hilliard, B.S.,<sup>2</sup> Philip C. Smith, Ph.D.,<sup>3</sup> Mary Anne Dooley, M.D., MPH,<sup>2</sup> Ronald J. Falk, M.D.<sup>2</sup>; (1) University of North Carolina, Schools of Medicine and Pharmacy, UNC Kidney Center, Chapel Hill, NC; (2) University of North Carolina, School of Medicine, Chapel Hill, NC; (3) University of North Carolina, School of Pharmacy, Chapel Hill, NC*

#### 208E. A randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking.

*Larry A. Dent, Pharm.D., BCPS, Kari J. Harris, Ph.D., MPH, and Curtis W. Noonan, Ph.D.; University of Montana, Skaggs School of Pharmacy, Department of Pharmacy Practice, Missoula, Montana; University of Montana, School of Public and Community Health Sciences, Missoula, Montana; University of Montana, Skaggs School of Pharmacy, Department of Biomedical Sciences, Missoula, Montana*

#### 213F. Pediatric renal transplant recipients' characteristics associated with IST adherence.

*Marie A. Chisholm-Burns, Pharm.D., MPH,<sup>1</sup> Christina Spivey, Ph.D.,<sup>1</sup> Mona Zawaideh, M.D.,<sup>2</sup> Rick Rehfeld, B.A.<sup>1</sup>; (1) The University of Arizona College of Pharmacy, Tucson, AZ; (2) The University of Arizona Department of Pediatrics, Tucson, AZ*

#### 221F. Kansas pharmacists' knowledge, attitudes, and beliefs regarding over-the-counter emergency contraception.

*LaDonna S. Hale, Pharm.D.,<sup>1</sup> Julie S. Shrack, PA-S,<sup>1</sup> Erin K. Stump, PA-S,<sup>1</sup> Gina M. Berg-Copas, Ph.D.(C)<sup>2</sup>; (1) Wichita State University, Wichita, KS; (2) Kansas University School of Medicine, Wichita, KS*